Primingtechnik mit Cisatracurium

Schmidt, Joachim; Albrecht, Susanne; Petterich, N.; Fechner, J.; Klein, Peter; Irouschek, Andrea

doi:10.1007/s00101-007-1226-5

Cited by 4 publications

(2 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Thus, we have to pay attention to decide the priming dose. No adverse effects were reported in recent studies that used a priming dose of cisatracurium 0.01 mg/kg [9,16,19]. Schmidt et al [19] demonstrated that high dose of priming of cisatracurium was effective to shorten the onset time of cisatracurium, but did not not recommended clinical routine use due to possible side-effects.…”

Section: Discussionmentioning

confidence: 99%

“…No adverse effects were reported in recent studies that used a priming dose of cisatracurium 0.01 mg/kg [9,16,19]. Schmidt et al [19] demonstrated that high dose of priming of cisatracurium was effective to shorten the onset time of cisatracurium, but did not not recommended clinical routine use due to possible side-effects. In our study, we used the same priming dose and priming interval as in Schmidt's study (cisatracurium 0.01 mg/kg, 3 minutes) and our findings were similar from Schmidt et al [19].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

The effect of low dose ketamine and priming of cisatracurium on the intubating condition and onset time of cisatracurium

Ahn

Kim

et al. 2012

Korean J Anesthesiol

View full text Add to dashboard Cite

BackgroundBoth ketamine and priming may accelerate the onset time of neuromuscular blocking agents. We investigate the effect of low dose ketamine and cisatracurium priming on the intubating condition and onset time of cisatracurium.MethodsAfter Institutional Review Board approval, 120 consecutive patients undergoing general anesthesia were randomly assigned to one of 4 groups. All patients were injected one of normal saline (group C), cisatracurium 0.01 mg/kg (group P), ketamine 0.5 mg/kg (group K) and combination of cisatracurium 0.01 mg/kg, and ketamine 0.5 mg/kg (group PK) diluted into a 5 ml solution, followed 3 minutes later by cisatracurium 0.15 mg/kg in group C and K, and 0.14 mg/kg cisatracurium in priming group. Onset time was recorded the electromyographical responses using single twitch and intubating conditions were evaluated at 60 seconds after cisatracurium administration.ResultsThe mean onset time was most significantly accelerated in Group PK and was also significantly more accelerated in Group P and K compared with Group C (P < 0.008). It was 112.7 ± 13.2, 91.4 ± 17.9, 84.9 ± 12.7 and 76.4 ± 8.3 seconds in Group C, P, K, and PK, respectively. Intubating conditions were significantly improved in Group P, K and PK than Group C (P < 0.008). Especially, Group PK showed most significant improvement of intubating conditions.ConclusionsThe combination of the low dose ketamine and cisatracurium priming accelerated the onset time and was improved the intubating conditions.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

The effect of low dose ketamine and priming of cisatracurium on the intubating condition and onset time of cisatracurium

Ahn

Kim

et al. 2012

Korean J Anesthesiol

View full text Add to dashboard Cite

show abstract

Cisatracurium inhibits the growth and induces apoptosis of ovarian cancer cells by promoting lincRNA-p21

et al. 2021

View full text Add to dashboard Cite

As a common muscle relaxant, cisatracurium has shown good antitumor effect on some tumors. Recent studies reported that cisatracurium could inhibit the progression of colon cancer by upregulating tumor suppressor gene p53. However, its role in ovarian cancer and its regulatory effect on p53 and p53 downstream targeting gene long intergenic noncoding RNA p21 (lincRNA-p21) is still unknown. Quantitative Real-time Polymerase Chain Reaction (qRT-PCR) was used to assess the expression of p53, lincRNA-p21 and miR-181b. Cell viability and proliferation were detected by CCK-8 assay and Edu staining, respectively. Wound-healing and Transwell assays were performed to determine the abilities of cell migration and invasion. Apoptosis was evaluated by TUNEL staining. Luciferase reporter assay was conducted to detect the relationship between lincRNA-p21 and miR-181b. As a result, cisatracurium could increase the expressions of p53 and lincRNA-p21 of ovarian cancer cell line (OVCAR-3) in a dose-dependent manner. In addition, cisatracurium significantly inhibited the proliferation, migration and invasion of OVACR-3 cells, and induced apoptosis. However, these above changes in biological function can be attenuated by lincRNA-p21 knockdown. Next, lincRNA-p21 could directly target miR-181b and negatively regulate its expression by luciferase reporter assay. In conclusion, cisatracurium inhibited the progression of OVCAR-3 cells through upregulation of lincRNA-p21 expression activated by p53 inhibiting miR-181b expression. The experimental results provide a new research idea for the application of cisatracurium in ovarian cancer.

show abstract

A randomised controlled trial comparing rocuronium priming, magnesium pre‐treatment and a combination of the two methods*

Kim

Jeon

et al. 2012

Anaesthesia

View full text Add to dashboard Cite

SummaryWe investigated whether magnesium sulphate combined with rocuronium priming shortens the onset of neuromuscular blockade, compared with these methods used alone. Ninety-two patients scheduled for general anaesthesia were randomly allocated to one of four groups: controls were given 0.6 mg.kg )1 rocuronium; patients in the prime group were given 0.06 mg.kg )1 rocuronium three minutes before a further dose of 0.54 mg.kg )1 rocuronium; patients in the magnesium group were given an infusion of 50 mg.kg )1 magnesium sulphate before rocuronium and patients in the magnesium and prime group were given both the magnesium sulphate and the priming dose of rocuronium. Tracheal intubation was attempted 40 s after the rocuronium injection. The time to onset of neuromuscular blockade was the primary outcome; duration of blockade and tracheal intubating conditions were also measured. The group allocation and study drugs were coded and concealed until statistical analyses were completed. The magnesium and prime group had the shortest mean (SD) onset time (55 (16) s; p < 0.001), and best tracheal intubating conditions (p < 0.05). No statistical difference was found for the duration of blockade. As for adverse events, a burning or heat sensation was reported in eight (35%) and six (26%) patients in the magnesium and magnesium and prime groups, respectively. The combination of magnesium sulphate and rocuronium priming accelerated the onset or neuromuscular blockade and improved rapid-sequence intubating conditions, compared with either magnesium sulphate or priming used alone.

show abstract

Primingtechnik mit Cisatracurium

Abstract: Our results show that only high dose priming of cisatracurium can significantly shorten the laryngeal onset time. However, clinical routine use is not recommended due to possible side-effects.

Cited by 4 publications

References 38 publications

The effect of low dose ketamine and priming of cisatracurium on the intubating condition and onset time of cisatracurium

The effect of low dose ketamine and priming of cisatracurium on the intubating condition and onset time of cisatracurium

Cisatracurium inhibits the growth and induces apoptosis of ovarian cancer cells by promoting lincRNA-p21

A randomised controlled trial comparing rocuronium priming, magnesium pre‐treatment and a combination of the two methods*

Contact Info

Product

Resources

About